Paragon 28 Inc. understated losses and overstated surgical product inventory and profit metrics, before executives’ departures and revised financials caused a series of three stock-price declines, an investor alleges.
The company said Aug. 8 that it had identified weaknesses in its accounting controls, Nicholas Tiedt says in a proposed class action filed Oct. 18 in the US District Court for the District of Colorado. The ankle and foot surgery tool maker acknowledged that for the year ending Dec. 31, 2023, it understated an earnings loss by $8.4 million or 86%; overstated its gross profit by $8.4 million or 5%; and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
